MarketReportsOnline.com adds Q3 2012 reports for Pharmaceuticals and
Healthcare industry of multiple Europe countries to its store. Following
are the report briefs:
Germany Pharmaceuticals and Healthcare Report Q3 2012
http://www.marketreportsonline.com/166282-germany-pharmaceu.html
While the increased consumption of generic medicines will have an impact on the overall
pharmaceutical market forecast for Germany, we note that government measures such as the three-year freeze on price rises for prescription drugs, as well as the implementation of mandatory discounts of up to 16% on patented drugs, will weigh more heavily on overall pharmaceutical market growth.
Poland Pharmaceuticals and Healthcare Report Q3 2012
http://www.marketreportsonline.com/165006-poland-pharmaceut.html
Despite numerous challenges, we continue to believe Poland is the most attractive pharmaceutical market in Central and Eastern Europe (CEE). While the long-awaited Drug Reimbursement Act introduced in Q112 faced fierce opposition from the public and members of the healthcare profession, and also resulted in volatility of pharmaceutical spending, we maintain our view of positive growth for 2012, projecting 1.6% year-on-year (y-o-y) expansion.
Portugal Pharmaceuticals and Healthcare Report Q3 2012
http://www.marketreportsonline.com/166300-portugal-pharmace.html
A year has passed since the EU/IMF/ECB’s rescue package was approved, and the obligations that form part of the economic adjustment programmed have had, and will continue to have, a central role in redefining Portugal’s pharmaceutical and healthcare market. Cost-cutting measures are continuous: generic drug prices dropped (again) in May 2012, this time by an average of 20%; new legislation enacted in March 2012 means that patented medicines will be subjected to automatic price cuts once their patent expires; and physicians are now obliged to prescribe by active ingredient. The implications of these cuts are widespread. Delays in payments are threatening the economic viability of many pharmacies and wholesalers’ operations, while Roche decided to suspend the supply of drugs to 23 public hospitals in February 2012 because of payment arrears. On the upside, Health Cluster Portugal reports that pharmaceutical exports now exceed those of wine or cork and that the sector has potential for further growth, while Portugal’s long-awaited intellectual property court began operations in March 2012, offering the manufacturers of patented drugs additional operational security.
Bulgaria Pharmaceuticals and Healthcare Report Q3 2012
http://www.marketreportsonline.com/166271-bulgaria-pharmace.html
While the recently appointed new heads at the Bulgarian Ministry of Health and the National Health Insurance Fund (NHIF) are now clearly looking at more aggressive mechanisms for cutting drug prices in the country, despite the short-term challenges we still believe the market is attractive and will generate high single-digit yearly growth over our five-year forecast period. Our 2012- 2013 industry forecast scenario for Bulgaria’s pharmaceutical market is governed by two main factors. Namely, short-term negotiations of medicine price cuts and the likelihood that the health ministry and the NHIF will push ahead with more far-reaching legislative changes to how Bulgaria prices its medicines.
Slovenia Pharmaceuticals and Healthcare Report Q3 2012
http://www.marketreportsonline.com/165013-slovenia-pharmace.html
Our view that Slovenia’s drug market is one of the most stable in the region remains in place despite the fact that - at the start of 2012 - the government published new measures to control public drug expenditure. The government’s methods are considerably less aggressive than those in other Central and Eastern European (CEE) markets, and are as such not expected to result in the market value decline.
Jordan Pharmaceuticals and Healthcare Report Q3 2012
http://www.marketreportsonline.com/164982-jordan-pharmaceut.html
The development of Jordan’s medical facilities and infrastructure, partly driven by the country’s aim to increase its attractiveness for medical tourists from across the globe, will provide solid longer-term commercial opportunities for companies involved in the field. However, makers of innovative medicines will continue to face market access barriers in the shape of unfavorable pricing and intellectual property (IP) regimes, while the authorities’ attempt to increase access to medicines is set to result in encouraging the use of cheaper generic medicines. Still, while we expect a decline in the patented drug market’s share of the total by value, the absolute value of the segment will increase.
Oman Pharmaceuticals and Healthcare Report Q3 2012
http://www.marketreportsonline.com/164996-oman-pharmaceutic.html
While a higher healthcare budget in 2012 and the expansion of healthcare facilities will be conducive to pharmaceutical companies operating in Oman, the country’s small population and strict price controls will continue to place downward pressure on overall values. Nevertheless, the population increasing and ageing will remain an attraction, especially as patented medicines continue to represent the bulk of pharmaceutical spending in the country.
Browse more Reports on Pharmaceuticals
@ www.marketreportsonline.com/cat/pharmaceuticals-market-research.html
More Reports by Business Monitor International @ www.marketreportsonline.com/publisher/business-monitor-international-market-research.html
Contact sales@marketreportsonline.com to order OR for further information.
Germany Pharmaceuticals and Healthcare Report Q3 2012
http://www.marketreportsonline.com/166282-germany-pharmaceu.html
While the increased consumption of generic medicines will have an impact on the overall
pharmaceutical market forecast for Germany, we note that government measures such as the three-year freeze on price rises for prescription drugs, as well as the implementation of mandatory discounts of up to 16% on patented drugs, will weigh more heavily on overall pharmaceutical market growth.
Poland Pharmaceuticals and Healthcare Report Q3 2012
http://www.marketreportsonline.com/165006-poland-pharmaceut.html
Despite numerous challenges, we continue to believe Poland is the most attractive pharmaceutical market in Central and Eastern Europe (CEE). While the long-awaited Drug Reimbursement Act introduced in Q112 faced fierce opposition from the public and members of the healthcare profession, and also resulted in volatility of pharmaceutical spending, we maintain our view of positive growth for 2012, projecting 1.6% year-on-year (y-o-y) expansion.
Portugal Pharmaceuticals and Healthcare Report Q3 2012
http://www.marketreportsonline.com/166300-portugal-pharmace.html
A year has passed since the EU/IMF/ECB’s rescue package was approved, and the obligations that form part of the economic adjustment programmed have had, and will continue to have, a central role in redefining Portugal’s pharmaceutical and healthcare market. Cost-cutting measures are continuous: generic drug prices dropped (again) in May 2012, this time by an average of 20%; new legislation enacted in March 2012 means that patented medicines will be subjected to automatic price cuts once their patent expires; and physicians are now obliged to prescribe by active ingredient. The implications of these cuts are widespread. Delays in payments are threatening the economic viability of many pharmacies and wholesalers’ operations, while Roche decided to suspend the supply of drugs to 23 public hospitals in February 2012 because of payment arrears. On the upside, Health Cluster Portugal reports that pharmaceutical exports now exceed those of wine or cork and that the sector has potential for further growth, while Portugal’s long-awaited intellectual property court began operations in March 2012, offering the manufacturers of patented drugs additional operational security.
Bulgaria Pharmaceuticals and Healthcare Report Q3 2012
http://www.marketreportsonline.com/166271-bulgaria-pharmace.html
While the recently appointed new heads at the Bulgarian Ministry of Health and the National Health Insurance Fund (NHIF) are now clearly looking at more aggressive mechanisms for cutting drug prices in the country, despite the short-term challenges we still believe the market is attractive and will generate high single-digit yearly growth over our five-year forecast period. Our 2012- 2013 industry forecast scenario for Bulgaria’s pharmaceutical market is governed by two main factors. Namely, short-term negotiations of medicine price cuts and the likelihood that the health ministry and the NHIF will push ahead with more far-reaching legislative changes to how Bulgaria prices its medicines.
Slovenia Pharmaceuticals and Healthcare Report Q3 2012
http://www.marketreportsonline.com/165013-slovenia-pharmace.html
Our view that Slovenia’s drug market is one of the most stable in the region remains in place despite the fact that - at the start of 2012 - the government published new measures to control public drug expenditure. The government’s methods are considerably less aggressive than those in other Central and Eastern European (CEE) markets, and are as such not expected to result in the market value decline.
Jordan Pharmaceuticals and Healthcare Report Q3 2012
http://www.marketreportsonline.com/164982-jordan-pharmaceut.html
The development of Jordan’s medical facilities and infrastructure, partly driven by the country’s aim to increase its attractiveness for medical tourists from across the globe, will provide solid longer-term commercial opportunities for companies involved in the field. However, makers of innovative medicines will continue to face market access barriers in the shape of unfavorable pricing and intellectual property (IP) regimes, while the authorities’ attempt to increase access to medicines is set to result in encouraging the use of cheaper generic medicines. Still, while we expect a decline in the patented drug market’s share of the total by value, the absolute value of the segment will increase.
Oman Pharmaceuticals and Healthcare Report Q3 2012
http://www.marketreportsonline.com/164996-oman-pharmaceutic.html
While a higher healthcare budget in 2012 and the expansion of healthcare facilities will be conducive to pharmaceutical companies operating in Oman, the country’s small population and strict price controls will continue to place downward pressure on overall values. Nevertheless, the population increasing and ageing will remain an attraction, especially as patented medicines continue to represent the bulk of pharmaceutical spending in the country.
Browse more Reports on Pharmaceuticals
@ www.marketreportsonline.com/cat/pharmaceuticals-market-research.html
More Reports by Business Monitor International @ www.marketreportsonline.com/publisher/business-monitor-international-market-research.html
Contact sales@marketreportsonline.com to order OR for further information.
No comments:
Post a Comment